Uveal Melanoma Approved Therapies & Global Pipeline

Last Update: Aug 16, 2023

DONATE

Approved Therapies

Company Product MOA Indication Approvals
ImmunocoreKIMMTRAK (tebentafusp)gp100-HLA-A*02:01-targeted TCR-anti-CD3 scFv bispecificUnresectable/metastatic uveal melanoma in patients who are HLA-A*02:01-positiveJan-22 (US), Apr-22 (EU), Jun-22 (UK, AU, CA)
Delcath SystemsHEPZATO KITChemotherapy (melphalan hydrochloride) for injection/hepatic delivery systemMetastatic uveal melanomaAug-23 (US)
Click for Product Revenues

Global Pipeline

Company Candidate MOA Indications Phase
IDEAYA BiosciencesDarovasertib + CrizotinibPKC inhibitor + cMET inhibitor1L HLA-A2-negative mUMIII
IDEAYA BiosciencesDarovasertib + CrizotinibPKC inhibitor + cMET inhibitorHLA-A2-positive mUMII
IDEAYA BiosciencesDarovasertib (IDE196)PKC inhibitorNeoadjuvant UMII
Linnaeus TherapeuticsLNS8801GPER agonistmUM (mono or +pembrolizumab)I/II
Vanquish OncologyPAC-1Procaspase 3 activatormUM (+entrectinib)Ib/II
Verastem OncologyVS-6766 + DefactinibRAF/MEK clamp + FAK inhibitorGNAQ/11+ mUMII
Merck/SyndaxPembrolizumab+EntinostatAnti-PD-1 + Class I HDAC inhibitormUMII
Foghorn TherapeuticsFHD-286BRG/BRM1 inhibitormUMI
RocheRO7293583anti-TYRP1/CD3 T cell engagerTYRP1+ melanomasI
ReplimmuneRP2Modified HSV-1 expressing anti-CTLA4mUM, lung, breast, GI cancers, liver metastases (mono or +nivolumab)I
NovartisDYP688GNAQ/GNA11?mUM, GNAQ/11 mutant melanomasI
InxMed (Shanghai)IN10018FAK inhibitor +- Cobimetinib (MEKi)mUMI
Turnstone BiologicsTBio-4101Tumor infiltrating lymphocyte therapy + PembrolizumabUMI
Hillstream BioPharmaHSB-1216IMCD modulator/ferroptosis inducermUMIND

Discontinued Programs

Company Candidate MOA Indications Phase
BioMed Valley DiscoveriesUlixertinib (BVD-523)ERK inhibitormUMII
MerckVorinostatHDAC inhibitormUMII
Array Biopharma/PfizerSotrastaurin + MEK162PKC inhibitor + MEKimUMIb
Bellicum PharmaceuticalsBPX-701HLA-A2-PRAME-directed TCR autologous T cellsAML/MDS or UMI
NovartisLX196 + HDM201PKC inhibitormUMI
Prelude TherapeuticsPRT811PRMT5 inhibitorUveal melanoma, high grade gliomaI

Pipeline does not include non-targeted treatments in unselected solid tumor trials.